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Introduction  
Alzheimer’s Disease (AD), the most common form of dementia, is a neurodegenerative 
disease characterized by a progressive loss of neural cells leading to nervous system dysfunction. 
The hallmark signs are memory loss and decreased abilities to make judgements and perform 
activities of daily living1. Because of the increasing lifespan of humans, the projected number of 
people 65 years and older diagnosed with AD is expected to reach 13.8 million by the year 
20502. Biologically, AD is characterized by deposition of beta-amyloid protein (Aβ) and tau 
neurofibrillary tangles (NFTs). The deposition of Aβ occurs due to the cleavage of amyloid 
precursor protein (APP) changing from α-secretase to β-secretase and γ-secretase. This change in 
enzymatic activity causes larger Aβ molecules to form which then stack on top of one another 
creating amyloid plaques3. NFTs accumulate when isoforms of tau, a microtubule-associated 
protein, begins to hyperphosphorylate and fold atypically1.  Over time, these accumulations of 
amyloid plaques and NFTs lead to brain shrinkage and atrophy causing the well documented 
signs of AD such as memory problems, impaired judgement, and personality changes1,4.  
AD is classified into two types, Familial Alzheimer’s Disease (FAD) and Sporadic 
Alzheimer’s Disease (SAD). FAD, also known as early-onset AD, accounts for approximately 
5% of all cases and occurs via genetic inheritance, beginning between the ages of 40 and 605. 
There are three genetic mutations that account for FAD, these are mutations in the genes that 
encode for presenilin 1 (a subunit of γ-secretase), presenilin 2 (assist in processing APP), and 
APP itself4. SAD, or late-onset AD, typically occurs after the age of 65. It is not entirely 
understood what causes SAD, but research indicates genetics, lifestyle, and environmental 
factors, such as diet, disease state, age, socioeconomic status, and educational level, impact its 
development5.  
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Hypotheses for AD development 
Over the past several decades there have been many advances in AD research; however, 
the cause is still unknown. Development of AD follows a well-documented path, known as 
Braak staging. First described in 1991, Braak staging has six distinctive phases of AD grouped 
into three units based on the location of NFTs. Stages I-II occurs in the transentorhinal and 
entorhinal regions, III-IV are in the limbic allocortex and its adjacent neocortex, and V-VI are in 
the neocortex6. Once AD begins there is no reversing the disease; in order to better understand 
the disease researchers have hypothesized over the causes of disease progression. The main 
hypotheses include the amyloid, tau, oxidative stress, cholinergic, N-methyl-D-aspartate 
(NMDA) receptor, and altered calcium homeostasis7-11. More recently, impaired glucose 
metabolism in the brain, pathogenic virus, and prion disease hypotheses have emerged as 
possible causes of AD10,12,13 (Figure 1). Each of these pathways will be explored in more detail 
but a brief description is included here. The amyloid and tau hypotheses are the most common as 
the presence of amyloid plaques and NFTs are the definition of AD. The amyloid hypothesis 
centers around the creation of amyloid plaques formed from longer sheets of Aβ40-42 while the tau 
hypothesis focuses on the accumulation of NFTs leading to neuron death7. In oxidative stress, 
neuronal hypoxia caused by an increase in reactive oxygen species (ROS) occurs7. With the 
cholinergic hypothesis, cholinergic function is lost leading to a decrease in the neurotransmitter 
acetylcholine (ACh) and subsequent increases in cholinesterase8. At the NMDA receptor, 
neuronal death occurs after excitotoxicity causes increased glutamate and decreased NMDA 
receptors. The altered calcium homeostasis hypothesis focuses on altered mitochondrial function 
due to changes in enzymatic activity. This decreased mitochondrial function causes defects in the 
electron transport chain, leading to production and deposition of Aβ7. More recently, high 
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carbohydrate diets causing impaired glucose metabolism in the brain due to a decrease in 
lipoprotein creation in the liver has been proposed as a possible mechanism of action10. In 2018, 
researchers proposed certain viruses, with emphasis on herpes simplex virus, have the ability to 
stimulate the accumulation of Aβ12. Lastly, prion disease, which occurs when the prion protein 
causes normal proteins in the brain to misfold, is considered a possibility for AD development14. 
This hypothesis centers around cellular prion protein (PrPC) acting as a cellular surface receptor 
for Aβ13.  
AD and nutrition 
Not only are researchers divided on the mechanism for AD development, but the research 
into diet and its impact on these hypotheses is limited. A focus on the daily consumption of 
complex carbohydrates; including vegetables, whole grains, fruit, nuts, seeds, and legumes has 
been emphasized, with a strong correlation between adherence to a Mediterranean diet and 
overall cognitive performance7,15. One study reported that consumption of vegetables, fruits, 
nuts, and fish were associated with improved subjective cognitive function when compared to the 
intake of meat and dairy15. A hybrid of the Mediterranean and Dietary Approach to Stop 
Hypertension (DASH) diets, the Mediterranean-DASH intervention for Neurodegenerative 
Delay (MIND) diet, has been developed to help delay the onset of cognitive decline16,17. This 
diet is high in nutrients that research has shown to slow cognitive decline and includes “…folate, 
vitamin E, carotenoids, and flavonoids”16. Therefore, an emphasis is placed on adding berries 
and dark leafy greens, while not emphasizing large consumption of fruit, dairy, potato, and fish. 
To date, studies have shown that a high adherence to the MIND diet may play a protective role 
against AD development17.   
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Literature Review 
1. Amyloid Hypothesis 
The large majority of research surrounding diet and AD centers around the amyloid 
hypothesis and the deposition of amyloid plaques. In healthy brains, α-secretase cleaves the vast 
majority of APP, releasing shorter, harmless fragments of Aβ, such as Aβ25 and Aβ38. In the 
brains of AD patients, β-secretase followed by γ-secretase, are highly active and cleave APP in 
different locations, releasing longer Aβ proteins, like Aβ40 and Aβ4218,19. Of these two longer 
proteins, more Aβ40 is produced; however, Aβ42 is more toxic due to a higher affinity for 
aggregating caused by its hydrophobic properties1. Amyloid plaques are a buildup of these longer 
Aβ sheets. Experiments have shown nutrients found in common foods can mitigate Aβ-induced 
damage by increasing α-secretase, decreasing β-secretase and/or γ-secretase, disrupting amyloid 
plaques, autophagy, and/or clearing Aβ across the blood brain barrier (BBB) (Figure 2)20-51.  
Specific nutrients reviewed to determine their effect on amyloid plaques were 
docosahexaenoic acid (DHA), extra virgin olive oil (EVOO), resveratrol, curcumin, 
epigallocatechin gallate (EGCG), salvianolic acid B (Sal B), and the fat-soluble vitamins, A, D, 
E, and K. DHA is an omega-3 fatty acid that is anti-inflammatory and commonly found in 
flaxseed oil, chia seeds, walnuts, and fish (among other things)52. EVOO, a cooking oil used 
commonly in both the Mediterranean and MIND diets, is an unsaturated fat that contains various 
isoforms of vitamin E as well as various phenolic compounds, flavonoids, and lignans53. 
Resveratrol, a polyphenol found in nuts, berries, wine, and dark chocolate, has strong 
antioxidant, anti-inflammatory, anti-cancer, and anti-ageing properties20. Curcumin, a nutrient 
found in turmeric, curry powder, and ginger, displays similar antioxidant, anti-inflammatory, and 
anti-cancer properties as resveratrol21. EGCG, a major polyphenol and catechin found in green 
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tea has been shown to have neuroprotective effects22. Sal B is a water-soluble derivative of 
caffeic acid that has been commonly used in Chinese medicine to treat coronary artery disease 
and cerebrovascular diseases54. Lastly, multiple research studies have shown a positive 
correlation between serum and plasma levels of fat-soluble vitamins and cognitive 
performance55-68.  Interestingly, an association has also been found between individuals using a 
vitamin K antagonist for their anticoagulant medication, such as Warfarin, and cognitive 
impairment69. 
Activation of α-secretase 
Compounds that have an ability to activate α-secretase would potentially be able to 
increase the production of harmless Aβ leading to a decrease in the harmful Aβ23. An in-vitro 
study showed Neuroprotection D1 (NPD1), an enzymatic derivative of DHA, was shown to 
activate α-secretase in a dose-dependent manner. In this study, overexpression of APP was 
induced in aging human neuronal-glial cells through transient-transfection with Swedish 
mutation APP. These cells were treated with NPD1 at concentrations of 0 nM, 50 nM, 100 nM, 
and 500 nM, with the greatest effect seen at 500 nM23. A second in-vitro study analyzed 
resveratrol’s ability to upregulate sirtuin 1 (SIRT1), a silent information regulator that is 
suppressed by Aβ(25–35). SIRT1 downregulates Rho-associated protein kinase 1 (ROCK1), an 
inhibitor of α-secretase20. This study incubated pheochromocytoma (PC12) cells with resveratrol 
at concentrations of 12.5 μM, 25 μM, 50 μM, or 100 μM 2 hours prior to the addition of  20 μM 
Aβ25-3520. A significant increase of SIRT1 expression and a decrease in ROCK1 expression were 
seen in western blot analysis showing the potential of resveratrol to upregulate α-secretase20. An 
in-vitro analysis looking into curcumins impact on human embryonic kidney cells (HEK293) 
overexpressing APP. Curcumin, tetrahydrocurcumin (THC), curcumin-isoleucine (Cur-Ile), 
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curcumin-phenylalanine (Cur-Phe), or curcumin-valine (Cur-Val) was added at a concentration 
of 50 μM, with analysis showing Cur-Ile, Cur-Phe, and Cur-Val stimulated α-secretase 
expression24. A second in-vitro study on curcumin conducted on PC12 cells showed that lower 
concentrations of curcumin were protective against Aβ-induced toxicity while higher 
concentrations increased toxicity25.  
Decreased activity of β-secretase and/or γ-secretase 
Through decreasing enzymatic activity of β-secretase and/or γ-secretase, the continued 
production of harmful Aβ may decrease23. An in-vitro study, looking at EGCG showed a 5-
minute incubation of green tea infusion inhibited β-secretase activity by as much as 27%, which 
increased to 38% after 60 minutes26. An in-vivo study utilizing an APP/Prresenilin-1 (PS1) 
double-transgenic mouse study indicated EGCG was able to ameliorate learning and memory 
impairment as seen in a Passive Avoidance Test and Morris Water Maze. Mice treated with 
EGCG showed decreased concentrations of amyloid plaques, decreased concentrations of APP, 
and decreased apoptosis of neurons with researchers proposing this activity being in part due t 
EGCGs effects on γ-secretase70.  
When looking at in-vivo research, vitamin A deficiency has been shown to increase 
deposition of Aβ in the brain and cerebral blood with supplementation of all-trans retinoic acid 
improving cognitive function27. One possible mechanism for this is through inhibiting β-
secretase-dependent APP cleavage28. In-vivo research into vitamin D has proposed a possible 
mechanism for clearing Aβ is vitamin D’s ability to elevate neprilysin, an enzyme that is shown 
to degrade Aβ and reduce concentrations of β-secretase29. Studies into vitamin D have shown 
significantly reduced amyloid plaques and improved cognitive performance with 
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supplementation of a D3 enriched diet, although it is important to note that rats with normal 
vitamin D levels did not show improvement in spatial performance with D3 supplementation29-32.  
Mechanisms by which vitamin E impacts AD include its effect on decreasing cholesterol 
synthesis. Studies have shown a strong positive correlation between hypercholesterolemia and 
Aβ production33. The relationship between cholesterol and AD centers around cholesterol 
increasing the activity of β- and γ- secretase34. Because vitamin E is a group of eight compounds, 
it can be confusing to know if it is a combination or just one of these isoforms that has the 
greatest benefit. Table 1 breaks down some of the research into the various forms of vitamin E as 
it relates to AD. Unfortunately, outcomes in human studies on vitamin E supplementation have 
ranged from reduced need of care and slowed disease progression to no effect or an increased 
cognitive decline35-38.   
Disruption of amyloid plaques 
Causing a conformation change in amyloid plaques has shown potential for decreasing 
overall amyloid load39-42,45. An in-vitro analysis on resveratrol using PC12 cells showed 25 μM 
resveratrol combined with 25 μM purified Aβ42 remodeled three Aβ42 conformers—soluble 
oligomers, fibrillar intermediates, and amyloid fibrils—into an alternative aggregation that is 
unstructured and nontoxic39. This occurs due to resveratrol binding to the N-terminus of Aβ42 
monomers, preventing the formation of oligomers longer than 1–2 nm. Similar results has been 
seen in-vitro utilizing curcumin40. In an in-vitro analysis, Sal B showed a significant inhibition of 
the formation of Aβ42 that was both dose and time-dependent. Although a mechanism for how 
Sal B inhibited Aβ42 was not proposed, researchers indicated fibrils of Aβ were converted into 
deformed aggregates. Incubation with Sal B occurred up to 7 days with 100 μM concentrations54. 
Additional In-vitro studies into vitamin K have indicated it has the potential to be an effective 
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anti-amyloidogenic drug due to it inhibition of Aβ accumulation and toxicity through binding to 
the Aβ monomer41. Additionally, in-vitro analysis using human neuroblastoma cells (SH-S5Y5) 
showed DHA interrupted the microenvironment of tyrosine in the Aβ42 backbone, thus reducing 
levels of soluble Aβ42 oligomers and inhibiting the formation of Aβ42 fibrils. While 5 μM DHA 
had no significant effect on fibril formation, 10 μM and 20 μM DHA decreased fibril formation 
by 32% and 41%, respectively42. 
EGCG has shown the ability to decrease Aβ generation in a dose-dependent manner, 
protect against Aβ-induced apoptosis, and inhibit fibrillization of Aβ22,43,44. A proposed 
mechanism for how EGCG is able to do this is via covalent bonding with Aβ, preventing its 
accumulation45. It is important to note that EGCG is not the only catechin in green tea nor is it 
the only antioxidant. It is likely the inhibition activity seen in the green tea infusion is due to the 
cumulative effect of all of the bioactive compounds found in green tea. In one in-vivo study, α-
secretase activity increased, overall plaque load was reduced by 50% and β-secretase and γ-
secretase activity decreased. Researchers concluded oral administration of EGCG was more 
effective then injection24,43,46.   
Autophagy  
Curcumin has also been shown to reduce Aβ42 toxicity through an in-vivo study 
comparing the effects of curcumin supplementation in mice47. After sacrifice, control mice 
showed well-formed amyloid plaques where treatment mice showed significantly reduced 
plaques in a dose dependent manner in both the hippocampus and cortex47. This same in-vivo 
study showed an increase in autophagy of APP-rich organelles. Additionally, Morris water maze 
test after six months of treatment with either control, low concentration, or high concentration of 
curcumin revealed that mice completed the maze faster in a dose dependent manner. When the 
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brains of the mice were extracted and analyzed it was determined that curcumin acts through the 
PI3K/Akt/mTOR pathway to stimulate the autophagy of APP-rich organelles allowing for the 
survival and proliferation of cells47. Although in-vitro and in-vivo research has shown the benefit 
of curcumin, two human studies, one a 6-month clinical trial and one a phase 2 double-blind 
study did not show any improvement in cognitive performance or levels of amyloid plaques48,49. 
This can potentially be caused by curcumin’s low bioavailability21.   
In one study on ambulatory AD patients, peripheral blood mononuclear cells (PBMCs) 
were collected and differentiated into macrophages. These macrophages were incubated 
overnight with either 1,25-dihydroxyvitamin D3 (1,25D3) at a final concentration of 0.01 to 0.1 
μM or curcuminoids at a concentration of 0.001 μM to 1 μM. Fluorescently labeled Aβ was also 
added, and fluorescence microscopy and enzyme-linked immunosorbent assay (ELISA) both 
revealed that 1,25D3 increased clearance of Aβ through phagocytosis in all cells, and 
curcuminoids significantly assisted in only 50% of cells. 1,25D3 stimulates transport of Aβ 
within the cell, while curcuminoids stimulate surface binding. It was determined in silico that 
1,25D3 binds to the genomic pocket of the vitamin D receptor (VDR), while curcuminoids binds 
to the non-genomic pocket50. 
Clearing Aβ across the Blood Brain Barrier 
One in-vivo study looking at the effects of EVOO on Aβ burden, showed after three and 
six months of EVOO consumption, Aβ concentrations in mice brains were significantly reduced 
by 24% and 29% respectively. Researchers found this reduction in Aβ load was possibly 
associated with clearance across the blood brain barrier. Additionally, mice in the six-month 
treatment group showed improvement in the burrowing and nest construction test compared to 
control where mice in the three-month treatment group showed no improvement. Researchers 
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proposed that clearing Aβ across the BBB could potentially prevent an accumulation of amyloid 
plaques in the brain51.  
2. Tau Hypothesis 
The Tau hypothesis for AD development goes hand in hand with Aβ accumulation; the 
presence of both being the definitive diagnosis of AD7. Tau proteins assist in the formation of 
microtubules, promotion of microtubule stability, and synaptic plasticity. In the tau hypothesis, 
NFTs are produced in the brain. This occurs through a chain reaction starting with tau protein 
developing an unhealthy ratio of repeating amino acid sequences in the microtubule-binding 
domain. A normal tau protein has around 77 serine/threonine sites that allow for phosphorylation 
of the protein. When hyperphosphorylation occurs, tau’s affinity for microtubules is decreased 
along with the overall stability of microtubules. As more tau proteins are hyperphosphorylated, 
they accumulate, forming NFTs. This accumulation of NFTs leads to neuron death and cognitive 
decline71. 
In-vitro studies have demonstrated that grape seed phenol extract, tannic acid, and 
oleuropein (a compound found in olives) has the ability to inhibit the accumulation of tau by 
breaking up preformed tau peptide aggregates and inhibiting their accumulation72-74. 
Additionally, in-vitro studies have shown grape seed phenol extract was able to breakdown 
preformed tau peptides72. In-vivo studies showed the effectiveness of grape seed phenol extract 
at reducing the phosphorylation of tau and EGCG at suppressing phosphorylated tau 
isoforms46,75,76.  
Similar to its effects on Aβ plaques, vitamins A and E have shown the potential to reduce 
the concentration of NFTs. Vitamin A shows this activity with supplementation of all-trans 
retinoic acid in in-vivo studies and is possibly due to retinoic acid’s ability to prevent tau 
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phosphorylation27,77,78. Vitamin E shows this action via trolox, an analog of vitamin E that is 
water soluble79. A second in-vivo study showed supplementation with α-tocopherol caused 
suppressed development of NFTs80. 
3. Oxidative Stress 
During oxidative stress, there is an imbalance between the production of ROS and their 
clearance from the body. As a result, neuronal hypoxia may occur, leading to neurodegeneration. 
Because the brain is more susceptible to free radical damage then other organs, oxidative damage 
can be both a potential cause of and result of Aβ deposition. The amyloid and oxidative stress 
hypotheses are closely linked due to APP and its derivatives causing excessive generation of 
ROS in mitochondria. This, coupled with oxidative stress, potentially causing increases in β-
secretase and γ-secretase, leading to increased plaque deposition7. 
ROS play a pivotal role in immune response and cell signaling and are created during 
normal physiological processes. In a healthy individual, endogenous antioxidant defense systems 
keep ROS at healthy levels7. Various mechanisms are known to increase the levels of ROS in the 
brains of patients with AD, including increasing amyloid plaque load and increasing 
excitotoxicity from the NMDA receptor81-83 . In order to maintain a healthy equilibrium between 
creation and degradation of ROS, a diet high in antioxidants is crucial7. Antioxidants scavenge 
ROS and inhibit their continued formation. By including antioxidants in the diet, they increase 
the effects of endogenous antioxidants84.  
Many vitamins, minerals, and polyphenols display antioxidant activity, including 
vitamins A, C, and E; selenium; and polyphenols such as resveratrol85. Antioxidants are 
primarily found in plant-based foods, such as teas, nuts, berries, dark chocolate, and fruit81. Due 
to the importance of antioxidants, the creators of the MIND diet emphasized consumption of 
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complex carbohydrates. The MIND diet includes ten categories of brain healthy foods (“…green 
leafy vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive oil, 
and wine…”) and five categories of unhealthy foods (“…red meats, butter and stick margarine, 
cheese, pastries and sweets, and fried/fast foods…”)16.  In one study of preclinical AD patients, 
the MIND diet was significantly associated with a decreased risk of developing AD. Individuals 
in the highest quartile of compliance had a 53% reduction in AD compared to the lowest 
quartile17.  
Resveratrol can also act in combination with melatonin to attenuate oxidative stress 
associated with Aβ42. An in-vitro study using HT22 hippocampal cells determined Aβ1-42 
induced cell death via oxidative stress in a dose dependent manner. Researchers measured levels 
of ROS as well as cell viability to show the effects of Aβ1-42 without treatment groups. The cell 
line was infected with 2 μM Aβ1-42 and treated with 0.1 μM to 20 μM resveratrol and/or 1 μM to 
500 μM melatonin. Using DCF fluorescence, it was determined that the maximum reduction of 
oxidative stress was achieved at concentrations of 20 μM resveratrol and 500 μM melatonin, and 
that co-treatment revealed synergistic effects. Spectrophotometry revealed that resveratrol and 
melatonin may reduce oxidative stress by preventing the depletion of glutathione, another 
antioxidant. Aβ treatment resulted in a glutathione decrease of 20%, and the addition of 
resveratrol and melatonin increased glutathione to at least control levels86. Another in-vitro study 
conducted rat primary cortex neurons using resveratrol as well as two other stilbenes, trans-4-
hydroxystilbene (THS) and trans-3’4’,3,5-tetrahydroxy-stilbene (PIC) showed the free radical 
scavenging ability of these compounds. THS showed the lowest effectiveness on ROS at 6.25%, 
followed by resveratrol at 13.07% and PIC at 26.82%. When compared with Aβ25-35, stilbenes 
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showed a significant dose-dependent decrease in ROS showing a possible neuroprotective effect 
of these nutraceuticals87.  
Cocoa extract is another high antioxidant/high polyphenol compound that can reduce the 
oligomer formation of Aβ42. In the presence of equimolar cocoa extracts, dimers, pentamers, 
and hexamers of Aβ42 were not formed while trimers and tetramers were greatly reduced. When 
looking at Aβ40 similar decreases were seen; trimers and tetramers were completely blocked by 
Levado extract and reduced by natural and Dutch cocoa extracts while dimers were reduced by 
Levado, natural, and Dutch cocoa extracts88.  A second in-vitro study looked at supplementation 
of cocoa extract and its protection from Aβ cytotoxicity due to oxidative stress. Researchers 
found the toxicity was attenuated and cell viability was increased with treatment of cocoa 
extract89. 
Lycopene, found in tomatoes and tomato products, is a carotenoid with strong 
neuroprotective, antioxidant, and anti-inflammatory activity. Lycopene is also studied due to its 
ability to cross the blood brain barrier and to specifically act as an antioxidant in the brain. One 
in-vitro study pre-treated primary cultured cortical neurons with lycopene, followed by Aβ25-35. 
Although researchers utilized the shorter, less toxic form of Aβ, they stated the peptide utilized in 
their experiments is shown to “…retain the toxicity of the full length Aβ…”90. What researchers 
found was the pre-treatment of lycopene significantly protected against neurotoxicity by 
reducing apoptosis and decreasing concentrations of ROS’s in a dose dependent manner90. 
4. Cholinergic Hypothesis 
The cholinergic hypothesis of AD is based on ACh, the major neurotransmitter within the 
cholinergic system, playing an important role in memory and learning7. ACh synthesis occurs in 
the presynaptic nerve terminal and is the byproduct of the enzyme choline acetyltransferase on 
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Acetyl Coenzyme A (Acetyl CoA) and choline. After ACh is synthesized, it is released into the 
synaptic cleft where it attaches to presynaptic and postsynaptic receptors, which in turn regulates 
both neurotransmission and further release of ACh. At this point ACh is broken down by 
acetylcholinesterase (AChE) into acetate and choline which go back into circulation to produce 
additional ACh91. During the development of AD (as well as in the ageing process), a loss of 
cholinergic function in the central nervous system (CNS) occurs and is associated with a 
measurable decrease in the amount of ACh and an increase in total cholinesterase in the brain7,92. 
This loss of ACh is hypothesized to contribute to cognitive decline7. Currently, the majority of 
pharmacological treatments for AD focus on AChE inhibition in order to slow down the 
breakdown of ACh which subsequently causes an increase in synaptic concentration of ACh as 
well as its neurotransmission regulatory effects. At this time, AChE inhibitors offer only modest, 
short-term relief during the early stages of cognitive decline91.  
Butyrylcholinesterase (BuChE) is a second neurotransmitter within the cholinergic 
system that is important in cholinergic neurotransmission regulation as well as the development 
of the nervous system8. In 41-80% of patients with advanced AD, BuChE activity is significantly 
enhanced  while AChE is decreased by 10-60% in the area of amyloid plaques and NFTs. 
Traditional treatment for AD targets AChE in order to prevent the breakdown of ACh, which 
delays the onset of AD but does not stop the progression of the disease8. Interestingly, when 
BuChE is inhibited, a dose-dependent increase of ACh is seen in the brain with BuChE 
remaining unaffected by increasing concentrations of ACh91. See Table 2 for examples of dietary 
components that may play a role in the cholinergic hypothesis for AD development.  
5. NMDA Receptor 
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NMDA receptors plays an important role in short and long-term memory, synaptic 
plasticity, and learning. When overstimulated it can produce free radicals and cause cognitive 
defects through neuron death7,93. NMDA receptor is a glutamate receptor that can either be 
bound to glutamate (an excitatory neurotransmitter) or glycine (an allosteric modulator)93. In 
normal conditions, glutamate homeostasis prevents the overaccumulation of glutamate. 
Additionally, NMDA receptors are highly sensitive with regulation occurring via PrPC. Higher 
concentrations of PrPC reduces the expression of NMDA receptors. During the pathogenesis of 
AD, increasing concentrations of Aβ in the brain causes overstimulation of glutamate, 
simultaneously Aβ binds to PrPC, removing its inhibitory role on NMDA receptor causing its 
concentration to increase. Excitotoxicity then causes the production of ROS, leading to neuron 
death, cognitive dysfunction, and ultimately AD94.  
Simultaneously, excitotoxicity causes an influx of calcium through the NMDA receptor 
which disrupts learning and memory and causes death to the cell7,94. In one study, walnuts were 
found to simultaneously increase NMDA receptor activity while decreasing excitotoxicity95. 
Researchers believed it was the combination of polyunsaturated fatty acids, antioxidants, and 
polyphenols found in walnuts that provided this neuroprotective effect as seen through 
decreasing concentrations of lipid peroxidation95. Similarly, another study looking at 
supplementation of vitamin D in rats found that rats consuming vitamin D had an increase in the 
expression of NMDA receptors which was positively associated with cognitive function96.     
Research into the effects of vitamin E on NMDA receptors has also been conducted. In-
vitro research on mouse embryonic stem cells induced toxicity of glutmate followed by treatment 
with either α-tocopherol or tocotrienol rich fraction (TRF) which was composed of 25% 
tocopherol and 75% tocotrienol. This post treatment of cells with vitamin E was conducted in 
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order to assess the neurorecovery properties of vitamin E against glutamate toxicity. Researchers 
found posttreatment with α-tocopherol and TRF reduced cell death in a dose-dependent manner 
with TRF having a greater effect then α-tocopherol alone. This increase in cell viability occurred 
due to α-tocopherol and TRF acting as antioxidants and reducing levels of ROS82.    
6. Altered Calcium Homeostasis 
Research into mitochondrial health has indicated that as we age the function of the 
mitochondria declines. This is important because the mitochondria are not only the site where 
bodies produce the majority of ATP for energy, but they also assist in maintaining calcium 
homeostasis7. Research has shown a decrease in mitochondrial function in AD patients within 
brain, fibroblasts, and blood cells97,98. Mitochondria dysfunction begins with a reduction in 
enzymatic activity within the mitochondria. This leads to defects in the electron transport chain, 
altered calcium homeostasis, and eventually AD due to increasing the likelihood of Aβ 
production and deposition7.  
Effect of nutraceuticals on mitochondria 
The composition of lipids in the mitochondrial membrane changes with age. One study 
suggests that as people grow older, the percentage of phospholipids containing DHA in the 
mitochondrial membrane increases99. The ability of mitochondrial membranes to change lipid 
composition as a result of a change in diet has been demonstrated in 8-month-old zebrafish, 
whose mitochondrial membranes contained a higher percentage of DHA after a diet high in 
DHA100. The same effect was found in eicosapentaenoic acid (EPA), another omega-3 fatty 
acid101; although additional research suggests that while DHA and EPA exhibit many similar 
biological effects, research has indicated that EPA, but not DHA, improved protein quality in 
mitochondria and mitigated loss of mitochondrial function in aged mice102. One human study 
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showed a substantial reduction in the risk of all-cause dementia for individuals who were in the 
highest quartile of plasma DHA levels103.   
Resveratrol (as an antioxidant) has been found to pick up electrons that have been leaked 
from the respiratory chain, increase the formation of antioxidant species, and participate in 
mitochondrial energy biogenesis104. One study showed resveratrol increased cell survival by 
mitigating the levels of ROS in the mitochondria, although the same study suggested that 
resveratrol increases the total amount of ROS in the cell83. As stated previously, resveratrol 
activates SIRT1, which in addition to its anti-amyloid properties,  regulates mitochondria 
function and energy metabolism105. Several polyphenols, including resveratrol, were found to 
affect mitochondrial biogenesis by upregulating the promoter of mitochondrial transcription 
factor A (Tfam)106. Other studies, however, suggest resveratrol actually induces apoptosis by 
upregulating the release of cytochrome c from the mitochondria, and increasing the expression of 
proapoptotic proteins while downregulating antiapoptotic proteins 107.  
Like resveratrol, curcumin is an antioxidant that has demonstrated neuroprotective effects 
by mitigating oxidative stress caused by mitochondrial dysfunction108. In the kidneys of diabetic 
mice, curcumin also protects mitochondria from the effects of hyperglycemia by modifying 
oxygen consumption rate, nitric oxide synthesis, and the levels of thiobarbituric acid-reactive 
substances (TBARS)109. A hybrid compound of curcumin and melatonin has been found to 
upregulate the expression of complexes I, II, and IV of the electron transport chain in 
mitochondria in the brain tissue of APP/PS1 mice110. Experiments with cancer cells in-vivo and 
adipocytes in-vitro have suggested that curcumin, as well as several derivatives, including 
bisdemethoxycurcumin (BDMC), can induce apoptosis by inducing the release of cytochrome c 
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from the mitochondria111,112. In contrast, a study using diabetic rat testicular cells has suggested 
that curcumin protects against mitochondria-dependent apoptosis113.  
In an in-vitro study, researchers indicated that vitamin D downregulates respiratory chain 
transcription in these cells and upregulates biosynthetic pathways instead, thus increasing cell 
growth and proliferation114. A similar study indicated vitamin D acts as a gatekeeper for the 
mitochondrial respiratory chain by suppressing the transcription of cytochrome c oxidase 
subunits II and IV. This downregulates the Krebs cycle and directs the cell toward biosynthetic 
pathways115. Interestingly, vitamin D receptors can be transferred from the nucleus to the 
mitochondria which would help to increase the biosynthetic pathways116. 
One in-vivo study on lycopene injected rats with Aβ42 and observed how treatment with 
lycopene at doses of 1, 2, and 4 mg/kg orally impacted their mitochondrial activity. What 
researchers found was a significant increase in mitochondrial complex enzyme (I, II, and IV) in 
both the cerebral cortex and hippocampus along with a significant restoration of mitochondrial 
redox activity. Additionally, lycopene treated rats performed better then control in a Morris 
water maze test117.   
A high-resolution respirometry system revealed Aβ and tau may work synergistically to 
reduce the oxidative phosphorylation capacity of mitochondria through chronic oxidative 
stress118. It has also been suggested that Aβ derived from the endoplasmic reticulum (ER), Golgi 
apparatus, or mitochondria-associates ER membranes (MAM) accumulates in the mitochondria, 
which disrupts Ca2+ homeostasis and increases the production of free radicals119. The above 
listed research into the effect of nutraceuticals on apoptosis has been conducted murine muscle 
cells, breast and gastric cancer cells, human adipocytes, diabetic rats with testicular 
abnormalities, and human proliferating keratinocytescells106,107,111-115. The variety of cell types 
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used can possibly explain some of the opposing effects seen in resveratrol and curcumin (Figure 
3).  
7. Impaired Glucose Metabolism 
A more recent hypothesis on the development of AD is it is caused by impaired glucose 
metabolism in the brain. Individuals diagnosed with type 2 diabetes in their mid-life as opposed 
to later in life are 1.5 times more likely to develop AD. Brain glucose hypometabolism can be 
detected through tomography imaging and is proposed as a possible tool for early diagnosis of 
AD. This link between glucose hypometabolism and AD development focuses on diets that are 
high in carbohydrates (with an emphasis on fructose and fructose-containing carbohydrates), 
inhibiting the liver from creating lipoproteins. This decrease in lipoprotein formation starve 
neurons of these nutrients causing the cascade effect of neurodegeneration10.  One study showed 
a negative correlation between glycemic load dietary pattern and overall cognition and 
performance on various neuropsychometric tests120.  
In one in-vitro study, cultured rat hippocampal cells were exposed to Aβ42, causing a 
reduction in the number of cells and neurite length. For cells simultaneously exposed to β-
hydroxybutyrate (a ketone body) they doubled the number of surviving cells and increased 
neurite overgrowth121. In two in-vivo studies, a ketogenic diet was found to reduce the overall 
volume of formed Aβ with one showing decreased concentrations of NFTs and improved 
cognitive function122,123. In one human study, 15 participants maintained a ketogenic diet with 
medium chain triglyceride (MCT) oil supplementation. In participants who maintained ketosis, a 
significant improvement in the AD Assessment Scale cognitive subscale score was observed. 
After participants returned to their previous diet their cognitive functions returned to baseline124.  
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One case study placed the participant on a ketogenic diet along with high intensity 
interval training (HIIT) until ketosis was reached. After sustained ketosis their Hemoglobin A1C 
was within normal limits and an improvement in spatial awareness and self-efficacy was evident 
each week125. A second case study had a patient consume a ketogenic and calorie restricted diet 
in addition to HIIT exercises. This patient entered ketosis within three weeks and saw a 26% 
increase in memory function score from baseline126.  
8. Pathogenic Viral 
The pathogenic viral hypothesis on AD progression is fairly new, with research 
conducted in 2018 suggesting certain viruses, like herpes simplex virus, may be responsible for 
the long and slow progression of AD12. Research had previously indicated that microbes are able 
to stimulate the formation of Aβ as a defense mechanism to stop the infectious process127. In 
genetic analysis, researchers found differential gene expression associated with various viruses 
like Epstein-Barr virus (EBV) and human herpesvirus 6A (HHV-6A) and sought to determine if 
patients diagnosed with AD showed genetic changes caused by viruses. What researchers found 
was an increased quantity of HHV-6A and human herpesvirus 7 (HHV-7) in the brains of 
patients who had passed away from AD12. Conducting a quick PubMed review of herpes simplex 
virus & diet brings up 58 articles but research into the way diet can reduce the impact of herpes 
simplex virus is lacking.    
9. Prion Disease 
In the prion disease hypothesis, Aβ oligomers bind to PrPc receptors on neurons and 
initiate signaling transduction pathways that ultimately lead to neuronal death128-131. In-vitro 
analysis has indicated PrPc is capable of mediating the toxic effects of Aβ due to Aβ42 having a 
high affinity for PrPc132. Subsequent in-vivo analysis determined PrPc was essential for the 
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toxicity caused by Aβ and mice lacking PrPc who had amyloid plaques showed no spatial 
learning or memory impairment133. When conducting a PubMed review of PrPc associated with 
AD and diet only three articles came back134-136. None of these articles discussed the impact diet 
has on the development of AD via prion disease.  
Summary 
In 1906, Dr. Alois Alzheimer first described amyloid plaques and NFTs137. What has 
become clear since that time is AD is more confusing then researchers initially imagined. In this 
paper, a discussion was had on some of the more popular hypotheses surrounding AD 
development, many of which are hard to distinguish from each other due to their similarities. 
Between the amyloid, tau, oxidative stress, cholinergic, NMDA, altered calcium homeostasis, 
impaired glucose metabolism in the brain, pathogenic virus, and prion disease hypotheses it 
becomes apparent how interconnected many of them are. For instance, does the generation of 
amyloid plaques cause ROS to form or does oxidative stress form ROS leading to the 
development of amyloid plaques? With all of the compelling research on the nine potential 
pathways it becomes apparent that AD likely utilizes multiple pathways simultaneously, creating 
some type of interconnected loop.  
Even more confusing than the cause of AD, is the role that diet plays on protecting 
humans from developing it. Human studies on diet and AD are limited and typically occur after 
an individual is already displaying signs of cognitive dysfunction35-38,48,49,103,124-126. At that point 
in time, all of the research is focused on slowing the pace of cognitive decline because of AD’s 
irreversible nature. Many of the bioactive compounds found commonly in plants, such as 
walnuts, berries, and dark leafy greens, can potentially modulate the formation of AD in multiple 
ways. Through this research we’ve learned the importance of antioxidants to remove ROS and 
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decrease amyloid load by targeting the various enzymes in the accumulation of amyloid plaques. 
Although the large majority of studies are looking at how diet impacts AD after it has already 
begun, the question remains, what is the right diet for a prolonged healthy life? While the 
evidence points towards the Mediterranean diet as an excellent option for long term health, does 
the MIND diet help slow the rate of cognitive decline once AD has started? What these diets 
have in common is a high consumption of antioxidant, anti-inflammatory, whole plant-based 
foods. Consuming these foods, like EVOO and resveratrol may help the body fight AD by 
decreasing the amount of ROS, keeping the mitochondria healthy, and reducing the potential 
build-up of amyloid plaques. One human study analyzed dietary patterns in patients over the 
course of 3.9 years and compared it to their degree of AD risk. What researchers found was a 
dietary pattern that was significantly associated with reduced risk of AD. It was also positively 
correlated with consumption of “…salad dressing, nuts, fish, tomatoes, poultry, cruciferous 
vegetables, fruits and dark and green leafy vegetables…” and negatively correlated with a 
consumption of “…high-fat dairy, red meat, organ meat, and butter…”138.  
Looking forward, research needs to focus more on all of the lifestyle factors that 
contribute to AD. A question remains about whether individuals genetically predisposed to AD 
can impact its development through modifying their lifestyle. Garcia-Escudero et al and Weuve 
et al have written about how not only diet, but disease state, age, socioeconomic status, and 
educational level all impact the development of AD5. African Americans are 2-3 times more 
likely than whites to have cognitive impairment as they age139. In fact, one study showed that 
stress over the course of your lifetime is associated with decreased cognition later in life with 
African Americans reporting higher stressful events in their lives140. In addition, a quick search 
of K-12 nutrition education programs shows that nutrition education comes from after school 
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programs and the school nutrition program, who is responsible for providing meals to children. 
From a nutritional standpoint it is easy to emphasis consuming a diet that is high in antioxidant, 
anti-inflammatory, whole foods; however, before recommending this, it is important to recognize 
what the possible barriers are to an individual getting what they need. Knowing whether they live 
in a food desert, what their financial/transportation situation is, and what education they have 
received about eating healthy can lead the conversation. In the previous study linking dietary 
patterns with risk of AD, the population consuming the diet with the lowest risk of AD tended to 
be younger, more educated, non-current smokers141. Future research needs to focus on bringing 
nutrition education to everyone and reducing the health disparities. Through incorporating 
education in the classrooms from a young age, a longitudinal study could show us the impact of a 
low-risk AD healthy diet throughout the life instead of focusing on preventing the further 
development of a disease that currently has no cure.  
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Figure 1: Summary of hypothesis leading to the development of Alzheimer’s Disease.  
 
 
 
Aβ: beta-amyloid protein; ROS: reactive oxygen species; ETC: electron transport chain; ACh: Acetylcholine; TChE: Total 
Cholinesterase; CNS: Central Nervous System: NMDA: N-methyl-d-aspartate 
 
 
 
 
 
 
 
 
 25 
 
Figure 2: Effects of diet on the amyloid hypothesis of Alzheimer’s Disease development 
 
 
Adapted from Rosenberg, et al18. DHA: docosahexaenoic acid; EGCG: epigallocatechin gallate; 
EVOO: extra virgin olive oil  
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Table 1: Summary of research into the impact of vitamin E isoforms on the amyloid hypothesis. 
α-tocopherol • Higher intake associated with reduced AD risk62-64 
• If γ-tocopherol levels are low, higher α-tocopherol levels are 
associated with higher Aβ load64 
• In-vivo study showed dietary supplementation along with N-
acetylcysteine and alpha-lipoic acid prevented cognitive decline142  
• α-tocopherol quinine is an oxidative metabolite of α-tocopherol and 
has been shown to improve memory in in-vitro studies143 
• α-tocopherol + α-tocopherol quinine shown to decrease Aβ 
accumulation and toxicity142 
γ-tocopherol • Higher plasma levels associated with lowered AD neuropathology144 
• One in-vitro study showed increased Aβ secretion with treatment due 
to increased expression of β- and  γ- secretase145  
δ -tocopherol  
 
• One in-vitro study showed increased Aβ secretion with treatment due 
to increased expression of β- and  γ-secretase145 
α-tocopherol + 
α-, β-, γ-, δ-
tocotrienol 
supplement 
• In-vitro analysis indicates it disrupts formation of Aβ42146 
• In-vivo analysis indicated an improvement in cognitive impairment 
and a decrease in Aβ deposition with supplementation146  
AD: Alzheimer’s Disease; Aβ: beta-amyloid protein 
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Table 2: Summary of research into dietary nutrients impact on the cholinergic hypothesis. 
Alkaloids Largest group of metabolites with ChE inhibitory activity at lower concentrations. 
Examples include physostigmine which decreases AChE but not BuChE and 
berberine, an isoquinoline alkaloid that inhibits ChEs and β-secretase activity in 
rabbits, and galantamine8  
Brava Oil Showed dose dependent inhibition of BuChE and AChE147  
Coumarins Display AChE inhibition with some showing good BuChE inhibition8 
Flavonoids Along with isoflavones have higher AChE activity. The number of hydroxyl 
groups on the B ring of a flavonoid influences the potency of BuChE inhibition 
with an increase in the number of hydroxyl groups decreasing BuChE inhibition. 
Examples include Galangin, a type of flavanol had strong anti-ChE activity with 
the most potent activity against BuChE8 
Lycopene In-vivo study showed reversal of AChE activity and improved performance on 
Morris water maze test117 
Mansa Oil Showed dose dependent inhibition of BuChE but not AChE147 
Prenyltransferase 
Inhibitors 
Have been used to rescue synaptic and cognitive deficits caused by overactivation 
of farnesylated proteins. GGTIs can act directly on neuronal cells and the CNS148 
Quinones Pro-oxidants needed for mitochondria respiration. Redox reactions may occur 
creating semiquinones and hydroquinones which can create additional ROS. Some 
also work as AChEi8 
Spanish Sage Inhibit AChE, is an antioxidant, anti-inflammatory, and displays estrogenic 
effects. Estrogenic agents are potentially protective in preventing or delaying 
neurodegeneration in AD149 
Stilbenes Secondary metabolites derived from phenylpropanoid pathway and includes 
Resveratrol. Stilbenes other than resveratrol (like Gnetol) have better AChE and 
BuChEi activity8 
Terpenic 
Compounds 
Built up from isoprene subunits and are the most numerous and structurally 
diverse group of secondary metabolites produced by plants. It takes higher 
concentrations of terpenes to inhibit ChE. Dihydrotanshinone and 
cryptotanshinone have the potential to cross the BBB8 
Tocotrienols Tocotrienols appear to be superior to tocopherols because of their better 
distribution in the fatty layers of the cell membrane. Overall reduces free radical 
markers decreases AChE150 
Xanthones Secondary metabolites produced by plants, fungi, and lichens. Generally weak 
ChE inhibitors but with a lipophilic side chain it improves8 
Vitamin A In-vivo studies indicate restored AChE activity with supplementation of all-trans 
retinoic acid151  
AChE: Acetylcholinesterase; AChEi: Acetylcholinesterase inhibitor; AD: Alzheimer’s Disease; BBB: 
Blood Brain Barrier; BuChE: Butyrylcholinesterase; BuChEi: Butyrylcholinesterase inhibitor; ChE: 
Cholinesterase;: GGTIs: Geranylgeranyl Transferase Inhibitor;  ROS: Reactive Oxygen Species 
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Figure 3: Cell type dependent effect of nutraceuticals on apoptosis 
 
 
Curcumin and resveratrol have shown opposing effects on mitochondria apoptosis depending on 
cell type. Vitamin D on the other hand has been shown to increase apoptosis.  
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